THYROLAR-0.25
LOE ApproachingNDAORALTABLET
Approved
Nov 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THYROLAR-0.25 is an oral tablet thyroid hormone replacement therapy approved in 1969. The product treats hypothyroidism and related thyroid disorders. Mechanism of action and specific pharmacologic class are not publicly disclosed in available data.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), indicating declining market opportunities and potential team consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on THYROLAR-0.25 offers minimal growth potential given the LOE-approaching lifecycle and absence of linked job openings. This role is best suited for professionals seeking stable, mature-product management experience in a competitive, price-sensitive market.
Brand ManagerField Sales Representative
Worked on THYROLAR-0.25 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.